Das MET-Gen kodiert eine Tyrosinkinaserezeptor, der wenn an an Hepatozytenwachstumsfaktor gebunden eine wichtige Rolle beim Zellüberleben, Embryogenese, Migration und Invassion spielt. Mutationen werden bei verschiedenen Tumoren gesehen: papilläres Nierenzellkarzinom, hepatozelluläres Karzinom und verschiedene weitere Tumoren im Kopf- und Hals-Bereich.
Beals RK et. al. (1976) Familial congenital bowing of the tibia with pseudarthrosis and pectus excavatum: report of a kindred.
None (1992) The met oncogene: from detection by transfection to transmembrane receptor for hepatocyte growth factor.
Bottaro DP et. al. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
Park M et. al. (1987) Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.
Dean M et. al. (1987) Chromosomal localization of the met proto-oncogene in the mouse and cat genome.
Dean M et. al. () The human met oncogene is related to the tyrosine kinase oncogenes.
Cooper CS et. al. () Molecular cloning of a new transforming gene from a chemically transformed human cell line.
Maina F et. al. (1996) Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development.
Schmidt L et. al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
Sunkara UK et. al. (1997) Bilateral osteofibrous dysplasia: a report of two cases and review of the literature.
Jeffers M et. al. (1997) Activating mutations for the met tyrosine kinase receptor in human cancer.
Giordano S et. al. (1997) A point mutation in the MET oncogene abrogates metastasis without affecting transformation.
Schmidt L et. al. (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.
Zhuang Z et. al. (1998) Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas.
Jeffers M et. al. (1998) The mutationally activated Met receptor mediates motility and metastasis.
Park WS et. al. (1999) Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.
Shen Y et. al. (2000) InIB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase.
Powell EM et. al. (2001) Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon.
Maina F et. al. (2001) Coupling Met to specific pathways results in distinct developmental outcomes.
Giordano S et. al. (2002) The semaphorin 4D receptor controls invasive growth by coupling with Met.
Carrolo M et. al. (2003) Hepatocyte growth factor and its receptor are required for malaria infection.
Boccaccio C et. al. (2005) The MET oncogene drives a genetic programme linking cancer to haemostasis.
Veiga E et. al. (2005) Listeria hijacks the clathrin-dependent endocytic machinery to invade mammalian cells.
Karol LA et. al. (2005) Familial osteofibrous dysplasia. A case series.
Campbell DB et. al. (2006) A genetic variant that disrupts MET transcription is associated with autism.
Engelman JA et. al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Zou C et. al. (2007) Lack of Fas antagonism by Met in human fatty liver disease.
Kaushansky A et. al. (2011) The crucial role of hepatocyte growth factor receptor during liver-stage infection is not conserved among Plasmodium species.
Rodgers JT et. al. (2014) mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert).
Mujtaba G et. al. (2015) A mutation of MET, encoding hepatocyte growth factor receptor, is associated with human DFNB97 hearing loss.
Finisguerra V et. al. (2015) MET is required for the recruitment of anti-tumoural neutrophils.
Gray MJ et. al. (2015) Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.